in pyoderma gangrenosum (PG) and severe COVID-19. Vilobelimab has been granted orphan drug designation for the treatment of PG by both the Food and Drug Administration (FDA) in the US and the ...

Vilobelimab is currently being developed for various indications, including pyoderma gangrenosum and severe COVID-19. The Company has recently reported positive Phase IIa results in PG and ...

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program ...

To help determine whether a patient with pyoderma gangrenosum is responding to treatment ... mild, moderate, or severe. Other data obtained from the registry included ulcer characteristics ...

One of these is a skin condition called pyoderma gangrenosum. It’s very uncommon, but it can be extremely painful and disfiguring. In rare cases, people with other related diseases or who get ...

Pyoderma gangrenosum (PG) is a rare autoimmune dermatosis considered to be one of the possible ... Both underwent multiple surgeries resulting in stomas and were treated with infliximab; however, ...

Investigating historic cases of pyoderma gangrenosum in myelodysplastic syndrome ... Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628-2638.